Appendix 1 – Notice for Phase 1 of Point-of-Care Testing Programme
Pursuant to clause 8 of the COVID-19 Public Health Response (Point-of-care Tests) Order 2021 (“Order”), I, as the Director-General of Health, hereby specify the following persons or class of persons to import, supply and sell point-of-care tests for COVID-19 for the purposes of clause 8 of the Order:
Name of Company | New Zealand Business Number |
Roche Diagnostics NZ Ltd | 9429039820518 |
Abbott Rapid Diagnostics | 9429032718850 |
Pantonic Health (Australia) or Arrotex Pharmaceuticals (NZ) Limited | 9429041542033 |
EBOS Group Ltd | 94290319988404 |
Ministry of Health | 9429000082440 |
Pursuant to clause 8 of the COVID-19 Public Health Response (Point-of-care Tests) Order 2021 (“Order”), I, as the Director-General of Health, hereby specify the following persons or class of persons to use point-of-care tests for COVID-19 for the purposes of clause 8 of the Order:
Pursuant to clause 9 of the COVID-19 Public Health Response (Point-of-care Tests) Order 2021 (“Order”), I, as the Director-General of Health, hereby specify the following point-of-care tests or class of point-of-care tests that are exempt from clause 7(b) of the Order:
Product Name | Manufacturer | Product Code |
SARS-CoV-2 Rapid Antigen Test (SD Biosensor) (Nasal) | SD Biosensor (South Korea) | 09365397043 |
PanBio COVID-19 Ag Rapid (Nasal) | Abbott Rapid Diagnostics Jena GmbH (Germany) | 41FK11 |
CareStart COVID-19 Antigen (Nasal) | Access Bio Inc (United States of America) | 7006576 |
Dated this 10th day of November 2021.
Dr ASHLEY BLOOMFIELD, Director-General of Health.